We begin by engineering your chosen target cell lines to stably co-express the specific target antigen and a highly sensitive reporter gene (e.g., luciferase). This ensures a direct and quantifiable readout of cell viability upon target cell lysis.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsThe landscape of gene and cell therapy is rapidly evolving, bringing forth groundbreaking therapeutic modalities like CAR-T cells, bispecific antibodies, and antibody-drug conjugates (ADCs). A critical challenge in their development is the need for highly sensitive, specific, and high-throughput assays to accurately assess their efficacy in mediating target cell killing. Traditional cytotoxicity assays, such as chromium release, often suffer from limitations including radioactivity, high variability, and low throughput, hindering efficient drug development. The TDCC reporter assay addresses these critical gaps, providing a robust, non-radioactive, and quantitative platform essential for preclinical validation and optimization of these complex biotherapeutics, thereby accelerating their journey from concept to clinic.
Fig.1 The three mechanisms for cytotoxic T cells (CTLs)-mediated cell death.1
Creative Biolabs' TDCC Reporter Assay provides specific and quantitative solutions for evaluating cell-mediated cytotoxicity, compound screening, antibody characterization, and functional analysis of cell therapies. By leveraging reporter gene technology, where target cells are engineered to express luciferase, we precisely measure cell viability. This principle allows for rapid, quantitative assessments, yielding high-quality, actionable data within 4 to 8 weeks to guide your drug discovery and development decisions.
We begin by engineering your chosen target cell lines to stably co-express the specific target antigen and a highly sensitive reporter gene (e.g., luciferase). This ensures a direct and quantifiable readout of cell viability upon target cell lysis.
Our experts meticulously optimize critical assay parameters, including the effector-to-target cell ratio, incubation times, and the concentration range of your therapeutic candidates, to achieve optimal sensitivity and specificity for your experimental setup.
Engineered target cells are co-incubated with the effector cells and your therapeutic agents under precisely controlled conditions. This step mimics the in vivo cellular interactions crucial for evaluating therapeutic efficacy.
Following incubation, the luminescence or fluorescence signal from the reporter gene is measured. A decrease in signal directly correlates with target cell killing, providing a quantitative measure of cytotoxicity.
Comprehensive data analysis is performed, including the generation of dose-response curves and calculation of EC50 values. You will receive a detailed experimental report with all raw data, analyzed results, and expert interpretations.
Fig.2 Assay workflow of our TDCC reporter assay.
A1: Our TDCC Reporter Assay is highly versatile and can evaluate a wide range of therapeutic modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T cells, CAR-NK cells, and other immune cell engagers designed to induce target cell death. We can customize the assay to fit your specific needs.
A2: The TDCC Reporter Assay offers significant advantages over traditional methods like Chromium-51 release. It is non-radioactive, provides higher sensitivity and specificity, allows for high-throughput screening, and simplifies the workflow, making it a safer and more efficient alternative for cytotoxicity assessment.
A3: Absolutely. Our TDCC reporter assay service is highly customizable. Our expert team can work closely with you to design and optimize the assay for unique target-effector cell combinations, specific antigen expressions, and diverse therapeutic mechanisms, ensuring the assay precisely addresses your research objectives.
A4: Upon completion, you will receive a comprehensive report including detailed experimental protocols, raw data, analyzed dose-response curves, EC50 values, and a summary of key findings. Our reports are designed to provide clear, actionable insights to guide your drug discovery and development decisions.
Creative Biolabs is dedicated to supporting your scientific advancements. Reach out to us for detailed information on our TDCC Reporter Assay service or to discuss your specific project needs. Our team of experts is ready to provide personalized solutions and accelerate your research.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
